Compare · GELS vs JNJ
GELS vs JNJ
Side-by-side comparison of Gelteq Limited (GELS) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GELS and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $573.71B, about 35008.2x GELS ($16.4M).
- Over the past year, GELS is down 60.6% and JNJ is up 53.7% - JNJ leads by 114.3 points.
- JNJ has been more active in the news (12 items in the past 4 weeks vs 4 for GELS).
- JNJ has more recent analyst coverage (25 ratings vs 0 for GELS).
- Company
- Gelteq Limited
- Johnson & Johnson
- Price
- $0.99-35.50%
- $240.84+1.06%
- Market cap
- $16.4M
- $573.71B
- 1M return
- +130.13%
- +4.51%
- 1Y return
- -60.56%
- +53.73%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 4
- 12
- Recent ratings
- 0
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest GELS
- Gelteq Successfully Completes Veterinary Palatability Trials with Kemin, Further Validating Gelteq® Technology for Animal Health Applications
- Gelteq Establishes Center of Excellence in China to Accelerate Product Development and Commercial Expansion
- SEC Form 6-K filed by Gelteq Limited
- SEC Form 6-K filed by Gelteq Limited
- Healthy Extracts Q1 2026 Net Revenue Up 73% to Record $1.6 Million, Driving Positive EBITDA
- Gelteq Announces USD $3.5 Million Strategic Debt Financing to Accelerate Commercialization and Support Revenue Growth
- Healthy Extracts Reports 2025 Net Revenue Up 45% to Record $4.5 Million
- Healthy Extracts Reports Preliminary 2025 Results, Net Revenue Expected Up 45% to Record $4.5 Million
- SEC Form 6-K filed by Gelteq Limited
- SEC Form 3 filed by new insider Wynne Paul Michael
Latest JNJ
- SEC Form 4 filed by Director Woods Eugene A.
- Johnson & Johnson Expands U.S. Availability of TECNIS PureSee IOL, an Advanced Lens Option for Cataract Surgeons and Patients
- IMAAVY® (nipocalimab-aahu) demonstrates durable hemoglobin response and rapid onset of effect in pivotal Phase 2/3 study in warm autoimmune hemolytic anemia (wAIHA), an autoantibody-driven disease with no FDA-approved therapies
- Johnson & Johnson Hit with $32 Million Verdict in Los Angeles Asbestos Trial
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform
- Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage